Blade Air Mobility, Inc. (BLDE) Q2 2025 Earnings Call Transcript

Blade Air Mobility (BLDE) announced the sale of its Passenger business, including the Blade brand, to Joby Aviation for up to $125 million, effectively transforming BLDE into a pure-play medical transport entity to be renamed Strata Critical Medical. This strategic divestiture aims to unlock shareholder value by separating the high-growth, profitable Medical division—which accounted for 60% of 2024 revenue and 85% of segment adjusted EBITDA—from the historically undervalued Passenger segment. The transaction is projected to be adjusted EBITDA and free cash flow neutral due to $7 million in corporate cost efficiencies, leaving Strata with approximately $200 million in cash to pursue organic growth and an aggressive M&A strategy in the fragmented medical air transport market. Strata's Medical revenue grew 17.6% in Q2 2025, with expectations for mid-teens revenue growth and 15% adjusted EBITDA margins in H2 2025, further supported by a long-term partnership with Joby for eVTOL access.

Analysis

Blade Air Mobility (BLDE) has announced a transformational divestiture, selling its entire Passenger business to Joby Aviation (JOBY) for up to $125 million. This strategic pivot will reshape the company into a pure-play medical logistics firm named Strata Critical Medical, focused on the high-growth, high-margin organ transport market. The rationale is to unlock value by separating the Medical division—which accounted for approximately 60% of revenue in 2024 and 85% of segment adjusted EBITDA—from the capital-intensive and historically undervalued Passenger segment. Financially, the deal is structured to be adjusted EBITDA and free cash flow neutral on an annualized basis, supported by an estimated $7 million in corporate cost savings. The new entity, Strata, will be well-capitalized with a pro forma cash balance of approximately $200 million, positioning it for an aggressive M&A strategy in a fragmented market. The core Medical segment demonstrated strong underlying momentum, with Q2 2025 revenue accelerating 17.6% year-over-year to $45.1 million. While adjusted EBITDA margins temporarily compressed to 13.4% due to elevated, scheduled aircraft maintenance, management guides for a recovery to approximately 15% in the second half of the year, alongside continued mid-teens revenue growth.

Key Decisions for Investors

• Investors should re-evaluate the company on a sum-of-the-parts basis, focusing on the new pure-play entity, Strata, as a high-growth medical logistics provider with a non-cyclical revenue stream and a clear path for market consolidation.
• The primary catalyst for value creation is now the effective deployment of the pro forma ~$200 million cash balance; therefore, focus diligence on management's ability to execute its articulated M&A strategy in the fragmented organ transport market.
• Monitor the Medical segment's near-term execution, specifically its ability to achieve the guided 15% adjusted EBITDA margin in H2 2025 as fleet uptime normalizes, which will be a key proof point for the stand-alone business's operational leverage and inherent profitability.